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Introduction
Aurora B (serine/threonine-protein kinase 12) is the enzymatic
core of a multiprotein complex, the chromosomal passenger
complex (CPC), which comprises other three non-enzymatic
subunits, INCENP, Survivin and Borealin (Carmena and Earnshaw,
2003; Ruchaud et al., 2007). The CPC is an important upstream
regulator of centromere-kinetochore function, and is responsible
for the recruitment to the kinetochore and centromere of a number
of proteins, including inner centromere-kinetochore proteins (Sgo1,
Sgo2, MCAK), regulators of the microtubule-kinetochore
interaction (such as Hec1 and Plk1, among others) and proteins
involved in the spindle-assembly checkpoint (SAC; such as Mad2,
BubR1 and Mps1) (Kelly and Funabiki, 2009; Ruchaud et al.,
2007). Some kinetochore components, including Hec1, Dam1,
MCAK and CENP-A, are Aurora-B substrates, suggesting a crucial
role for the CPC in the destabilization of aberrant microtubule-to-
kinetochore attachments and in the SAC-dependent delay of mitotic
progression until these defects are corrected. Recent data suggests
that substrate phosphorylation depends on the distance of the
substrate from Aurora B at the inner centromere, and artificial
recruitment of the CPC to the kinetochore prevents the stabilization
of improper attachments and activates the SAC to delay the
metaphase-to-anaphase transition (Kelly and Funabiki, 2009; Liu
et al., 2009). During cytokinesis, Aurora B is localized to the mid-
body where its local inactivation is crucial for completion of
abscission (Guse et al., 2005; Steigemann et al., 2009).
Activity of Aurora B is regulated through several mechanisms,
including controlled interactions with INCENP, Survivin and
Borealin. Knockdown of any member of the complex delocalizes
the others, disrupts mitotic progression and might destabilize one
or more subunits (Jeyaprakash et al., 2007; Ruchaud et al., 2007).
In addition, several post-translational modifications are known to
be required for proper activity and control of the dynamic behavior
of the CPC. Activation of Aurora B is triggered by
autophosphorylation of the T-loop residue after association with its
substrate, INCENP. Full activation involves a positive-feedback
loop after Aurora-B phosphorylation of INCENP in the conserved
IN-box region, possibly as a result of structural rearrangements
(Bishop and Schumacher, 2002; Honda et al., 2003).
CPC function is also modulated by ubiquitin and ubiquitin-
related modifiers. Aurora B is targeted by a Cul3-containing SCF
ubiquitin ligase during early mitosis (Sumara et al., 2007).
Interestingly, this modification is necessary to remove a fraction
of Aurora B from mitotic chromosomes, allowing its accumulation
on the central spindle during anaphase. In the absence of this
SCF-Cul3 ubiquitin ligase, Aurora B spreads along chromosome
arms and fails to dissociate from them during anaphase. Aurora
B also requires APC/C-Cdh1 activity to efficiently translocate to
the spindle mid-zone in anaphase. In APC/C-Cdh1-depleted cells
Aurora B and the CPC prematurely accumulate in the equatorial
cortex, resulting in a weak anaphase spindle (Floyd et al., 2008).
Finally, after completion of cytokinesis, the remaining pool of
Aurora B is targeted for degradation by APC/C-Cdh1 (Floyd et
al., 2008; Garcia-Higuera et al., 2008). These post-translational
modifications also affect other CPC components. For instance,
Survivin is ubiquitylated during mitosis and its deubiquitylation
is required for Survivin dynamics at centromeres (Vong et al.,
2005).
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Summary
Aurora kinases are central regulators of mitotic-spindle assembly, chromosome segregation and cytokinesis. Aurora B is a member of
the chromosomal passenger complex (CPC) with crucial functions in regulation of the attachment of kinetochores to microtubules and
in cytokinesis. We report here that Aurora B contains a conserved SUMO modification motif within its kinase domain. Aurora B can
bind SUMO peptides in vitro when bound to the IN-box domain of its CPC partner INCENP. Mutation of Lys207 to arginine (Aurora
BK207R) impairs the formation of conjugates of Aurora B and SUMO in vivo. Expression of the SUMO-null form of Aurora B results
in abnormal chromosome segregation and cytokinesis failure and it is not able to rescue mitotic defects in Aurora-B-knockout cells.
These defects are accompanied by increased levels of the CPC on chromosome arms and defective centromeric function, as detected
by decreased phosphorylation of the Aurora-B substrate CENP-A. The Aurora-BK207R mutant does not display reduced kinase activity,
suggesting that functional defects are probably a consequence of the altered localization, rather than decreased intrinsic kinase activity.
These data suggest that SUMOylation of Aurora B modulates its function, possibly by mediating the extraction of CPC complexes
from chromosome arms during prometaphase.
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Post-translational modifications by the covalent attachment of
small ubiquitin-related modifiers (SUMOs) are important in several
cellular processes, including the cell-division cycle (Geiss-
Friedlander and Melchior, 2007; Hay, 2005; Ulrich, 2008). In
vertebrates, at least three SUMO forms (SUMO1, SUMO2 and
SUMO3) are covalently attached to a lysine residue in the target
protein in three enzymatic steps analogous to the ubiquitylation
cascade. SUMO conjugation requires a SUMO-activating E1
enzyme (SAE1 or SAE2), the SUMO-conjugating E2 enzyme
UBC9 and, in some cases, additional E3 SUMO ligases (Hay,
2005). SUMO modification is reversible by the action of SUMO-
specific isopeptidases that belong to the family of ubiquitin-like
proteases (ULPs), also known as sentrin-specific proteases (SENPs)
(Hay, 2007). Recent work has revealed the importance of
SUMOylation for mitotic progression (Dasso, 2008; Watts, 2007)
and has suggested a crucial role of SUMO modifications in
kinetochore and centromere function (Dawlaty et al., 2008; Di
Bacco et al., 2006; Mukhopadhyay et al., 2010; Zhang et al.,
2008), including direct SUMOylation of the CPC component
Borealin (Klein et al., 2009).
In this manuscript, we provide evidence for SUMOylation of
Aurora B at Lys207. Mutation of this residue results in abnormal
mitotic progression and the generation of multinucleated cells. In
those mutant cells, Aurora B and INCENP display an abnormal
localization at the chromosome arms during prometaphase and
metaphase and defective CENP-A phosphorylation, indicating a
role for Aurora-B SUMOylation in the proper localization and
activity of the CPC during chromosome alignment.
Results
A conserved SUMOylation motif in Aurora-B proteins
Aurora B contains a consensus motif for SUMO modification (-
Lys-x-Glu, in which  is a hydrophobic residue and x, any residue)
within the kinase domain (Fig. 1A). This motif is readily identified
by using different protein- domain-recognition algorithms (see the
Materials and Methods). The SUMO motif is conserved among
Aurora-B orthologues from yeast to human, and it is also present
in the other mammalian members of the Aurora family, but not in
other cell cycle kinases, including Polo-like kinases (Fig. 1A).
To test the possible SUMOylation of this domain, we mutated
the lysine (K207) predicted to accept the SUMO peptide into a
charge-conservative arginine residue. The Aurora-BK207R mutation
is predicted to impair covalent binding of SUMO with little effect
on the overall kinase structure. Next, we expressed V5-epitope-
tagged versions of wild-type (WT) Aurora-B and Aurora-BK207R
mutant forms along with the E2 SUMO ligase UBC9 and HA-
tagged versions of the three SUMO isoforms (HA-SUMO1 to HA-
SUMO3; ~12 kDa) in HEK293 cells (Fig. 1B). The ectopically
expressed proteins were immunoprecipitated using anti-V5
antibodies and detected with antibodies against the HA epitope.
The predicted SUMO-Aurora-B conjugates (~50 kDa) were
detected after expression of all three SUMO isoforms (Fig. 1B),
suggesting that Aurora B can be SUMOylated by the three SUMO
peptides in this assay. Importantly, the Aurora-B-SUMO conjugates
were not observed in cells expressing the Aurora-BK207R isoform,
indicating that K207 is required for covalent modification of Aurora
B by SUMO residues.
We next tested SUMOylation of endogenous Aurora B by taking
advantage of HeLa cells stably expressing histidine-tagged SUMO2
proteins (~16 kDa). These cells were transfected with V5-Aurora-
B-expressing vectors and SUMO2 conjugates were exposed to
antibodies against V5 or two different antibodies against Aurora B.
SUMO2 conjugates were affinity purified under denaturing
conditions with Ni-NTA beads. As depicted in Fig. 2A, all these
three antibodies detected a band of ~60 kDa, and possibly additional
higher-molecular-weight bands in SUMO2 conjugates. This band
was detected in taxol-treated cells and it was barely visible in
asynchronously growing cells or in parental cells that do not
overexpress SUMO2 (data not shown). An additional band of ~55
kDa that might correspond to the endogenous Aurora-B-
(His)SUMO2 conjugates is detected by a monoclonal antibody
against Aurora B. In fact, this band was also observed in similar
assays in which the V5-Aurora-B vector was not used (data not
shown), thus further suggesting modification of the endogenous
protein.
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Fig. 1. A SUMOylation motif in Aurora B. (A)Multiple sequence alignment
of Aurora B proteins from different species using Clustal software. Mm, Mus
musculus; Rn, Rattus norvegicus; Hs, Homo sapiens; Xl, Xenopus laevis; Dm,
Drosophila melanogaster; Ce, Caenorhabditis elegans; Sc, single Aurora
family member (Ipl1) from Saccharomyces cerevisiae. The SUMO motif
(green box) is highly conserved in all these Aurora-B proteins, as well as in
Aurora A and Aurora C, but it is not present in Polo-like kinase 4 (Plk4), a
close mitotic relative of these mitotic kinases. The kinase domain is shown in
dark blue, whereas the degradation motifs (KEN, A- and D-boxes) are
represented as red boxes. Note that the SUMO motif is located one residue
downstream of the aspartate (D205) that is crucial for ATP binding. Residue
numbers correspond to the mouse Aurora-B protein. (B)In vivo SUMOylation
of Aurora B at K207. HEK293 asynchronous cells were transiently transfected
with vectors expressing V5-Aurora-B WT, Aurora BK207R, HA-SUMO1,
-SUMO2 or -SUMO3 and the E2 SUMO ligase UBC9, as indicated. The
empty vector pDEST-V5 was used as a negative control. V5-Aurora-B
proteins were immunoprecipitated (IP) 48 hours after transfection using anti-
V5 antibodies and immunoblotted (IB) with antibodies against the HA and V5
tags. Aurora-B-SUMO conjugates are found after detection of the HA and V5
tags in cells transfected with WT V5-Aurora-B but not in cells transfected with
the V5-Aurora-BK207R mutant form. V5-Aurora-B immunoprecipitated in all
lanes. Mouse IgGs are indicated with an asterisk.
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We then used a reconstituted in vitro SUMO modification system
to further test the molecular requirements for this SUMOylation.
Recombinant Aurora B was incubated with SUMO E1-activating
enzymes (SAE1/2), the E2-conjugating enzyme UBC9 and SUMO2
in the presence of ATP. A mutant SUMO2 molecule unable to
conjugate to substrates was used as a control. As recently suggested
(Klein et al., 2009), we did not detect obvious SUMOylation of
Aurora B in this assay, whereas p53 was significantly SUMOylated
by SUMO2, but not SUMO2 mutant peptides (Fig. 2B). Since
Aurora B seems to be SUMOylated in vivo, we then asked whether
additional CPC domains were required for this post-translational
modification. Indeed, higher-molecular-weight Aurora B conjugates
(Fig. 2B, arrows) were observed after incubation of Aurora B with
the IN-box segment of INCENP, a domain that directly binds and
activates Aurora B (Adams et al., 2000). INCENP-bound Aurora
B was conjugated with SUMO2, but not with SUMO2 mutants,
indicating the specificity of this signal. All together, these results
suggest that Aurora-B K207 can be conjugated to SUMO residues
and this modification requires binding of Aurora B to its activator
INCENP.
Defective SUMOylation of Aurora B results in abnormal
chromosome segregation and reduced cell viability
We transiently transfected HEK293 cells with GFP-tagged vectors
for wild-type Aurora B, kinase-dead mutants (Aurora BK111M and
Aurora BD205A) and the SUMO-null form (Aurora BK207R) to
understand the relevance of SUMOylation of Aurora B in cell-
cycle progression. Overexpression of wild-type Aurora B slightly
increased the percentage of 4N and >4N cells, which is consistent
with a mitotic delay and defects in completion of cytokinesis.
These defects were more pronounced upon expression of the
kinase-dead form Aurora BK111M (19.1% of >4N) and, at an even
higher degree with Aurora BD205A (47.6% of >4N) (Fig. 3A,B).
The phenotypic differences observed with the Aurora-BK111M and
Aurora-BD205A mutants suggest distinct degrees of inhibition of the
kinase activity in these mutants (see below). Interestingly,
overexpression of the SUMO-null form (Aurora BK207R) induces
polyploidy at the same level as the Aurora-BD205A mutant (44.1%
in Aurora-BK207R mutants vs 47.6% in Aurora-BD205A mutants).
Microscopy analysis indicated that >4N cells overexpressing the
Aurora-BK207R mutant were mostly multinucleated and displayed
severe nuclear abnormalities (Fig. 3C), which were similar to those
of kinase-dead mutants (not shown). Stable expression of Aurora
BD205A and Aurora BK207R in U2OS cells severely reduced the
number of colonies, suggesting that mutations in these residues
impair Aurora-B function in a way that is incompatible with cell
proliferation (Fig. 3D,E).
Altered mitotic progression and cytokinesis in Aurora-
BK207R mutants
Deregulation of the function of Aurora B by chemical inhibition,
small interfering RNA (siRNA) or overexpression of the kinase-
dead form all lead to similar phenotypes, including chromosome
misalignment and failure to complete cytokinesis, resulting in
multinucleated cells (Ruchaud et al., 2007). To gain further
insights into the cellular consequences of defective Aurora-B
SUMOylation, we analyzed stable HeLa cell lines expressing the
different mutant constructs. As reported above, proliferation of
clones stably expressing GFP-Aurora-B fusion proteins was
relatively normal, whereas expression of the kinase-dead and
SUMO-null forms resulted in reduced viability. Accumulation of
the GFP-Aurora-B fusion protein was mostly observed in G2-M
cells (Fig. 4A) in agreement with its role at these cell-cycle
stages. The Aurora-B mutants exhibited a slightly lower
percentage of GFP-positive cells (4.3% and 3.0% in GFP-Aurora-
BD205A and GFP-Aurora-BK207R, respectively, vs 5% in GFP-
Aurora-BWT). Strikingly, the accumulation of these mutant
proteins was not restricted to G2-M. This altered behaviour of
the mutants might be explained by a higher stability of the mutant
proteins or by the existence of aneuploid cells with a DNA
content other than 4N.
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Fig. 2. In vivo and in vitro SUMOylation of Aurora B. (A)HeLa-SUMO2
or parental cells were transfected with UBC9 or V5-Aurora-B-expressing
vectors as indicated. Cells were harvested after 18 hours in the presence of
taxol or 3 hours after release from taxol. His-SUMO2 conjugates were
recovered on Ni-NTA beads and analyzed by immunoblotting (IB). The
indicated antibodies were used for immunoblot analysis on total protein lysates
(input) or SUMO2 conjugates purified with Ni-NTA beads. The position of
V5-Aurora-B-SUMO2 conjugates (~60 kDa and higher) is indicated by
brackets. An additional band of ~55 kDa (predicted size for SUMO conjugates
with endogenous Aurora B) is detected by the mouse monoclonal antibody
against Aurora B. The asterisk indicates an unspecific band detected by the
rabbit, but not the mouse, anti-Aurora-B antibody. (B)In vitro SUMOylation
of Aurora B. Recombinant p53, Aurora B or Aurora B in complex with the IN-
box of INCENP were incubated in the presence of SUMOylation machinery
and SUMO2 or a SUMO2 non-conjugatable mutant. Proteins were
immunodetected using specific antibodies against the indicated proteins. p53-
or Aurora-B-SUMO2 conjugates are indicated by arrows.
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We then depleted endogenous Aurora B by siRNA in the stable
clones expressing GFP-Aurora-B fusion proteins. The mouse Aurkb
cDNA, encoding Aurora B, was used to generate these constructs
and they were therefore resistant to siRNA treatment directed
against the endogenous human transcript (Fig. 4B). The wild-type
GFP-Aurora-B construct efficiently rescued the formation of
multinucleated cells after depletion of endogenous Aurora B
proteins and these rescued cells progressed normally through
mitosis (Fig. 4C). However, the expression of Aurora-BD205A and
Aurora-BK207R mutants failed to rescue the defects caused by
knockdown of the endogenous protein. These cultures delayed in
prometaphase with unaligned chromosomes, failure to execute
cytokinesis and accumulation of multinucleated cells (Fig. 4C,D).
Similar results were observed after chemical inhibition of Aurora-
B kinase activity with ZM447439 (ZM1; Fig. 4C,D). Quantification
of the distribution of mitotic phases in these stable cell lines after
depletion of endogenous Aurora B confirmed that expression of
GFP-Aurora-BD205A and GFP-Aurora-BK207R provokes a similar
arrest at prometaphase and a reduction of cells in telophase (Fig.
4E). This was accompanied by a decrease in the percentage of cells
in cytokinesis. Furthermore, those cells that were undergoing
cytokinesis in cultures expressing Aurora BD205A and Aurora BK207R
were mostly aberrant and frequently displayed chromosomal
bridges between the two daughter cells (Fig. 4F).
Altered chromosomal dynamics of the CPC in Aurora-
BK207R mutants
Endogenous Aurora B concentrates in the centromeric region of
chromosomes during prometaphase, similarly to other CPC
components such as INCENP. In the absence of endogenous Aurora
B, both INCENP and exogenous wild-type GFP-Aurora-B localized
properly to these centromeric structures, consistent with the
functional rescue by this wild-type protein (Fig. 5A,B).
Interestingly, the Aurora BK207R mutant (as well as the kinase-dead
isoform) was dispersed along the entire chromosome arms in
prometaphase (PM) and metaphase (M) cells. INCENP also failed
to concentrate in inner centromeres, suggesting that there are CPC
localization defects upon lack of Aurora B SUMOylation. Further
analysis of the distribution of Aurora B using Metamorph
algorithms confirmed that Aurora BD205A and Aurora BK207R were
dispersed along the chromosome arms (Fig. 5C-E). Quantification
of the integrated optical density (OD), a measure of the opacity of
an object when exposed to light, showed that the chromosomal
staining of the SUMO-null Aurora B mutant is significantly
(P<0.001) less opaque than Aurora-BWT staining. This means that
Aurora BK207R does not concentrate at any chromosomal region
(Fig. 5E). These defects were reduced in the kinase-dead mutant
and did not reach statistical significance in this assay. We also
tested whether Aurora-B kinase activity was important for proper
localization of Aurora B in the centromere, by treating GFP-
Aurora-BWT cells with the ZM1 inhibitor. In agreement with
previous reports (Ditchfield et al., 2003; Xu et al., 2009), chemical
inhibition of Aurora B kinase activity did not perturb localization
of Aurora B or INCENP to the centromere, indicating that an
active kinase is not required for their centromeric localization (Fig.
5F).
Since the presence of endogenous Aurora B might interfere with
the localization of exogenous Aurora-BK207R mutants, we decided
to further study these mutants in Aurora-B-knockout cells. These
cells derive from Aurora-B conditional-knockout mice in which
exons 2 to 6 are flanked by loxP sites [Aurkb(lox) allele; G.F.-M.,
I.P.C. and M.M., unpublished results]. Upon expression of the Cre
recombinase (Fig. 6A), exons 2 to 6 are excised, resulting in a null
allele [Aurkb()]. Aurkb(/) MEFs progress normally through
prophase and prometaphase. However, whereas 65% of mitotic
cells (n40 of each genotype) were in metaphase, anaphase or
telophase in Aurkb(lox/lox) cultures, these figures were reduced to
8% in Aurkb(/) cells (most of these anaphases and telophases
showed immunoreactivity against Aurora B, probably as a
consequence of inefficient gene deletion; data not shown).
Aurkb(/) prometaphases displayed several misaligned
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Fig. 3. Aurora BK207R induces polyploidy and defective cell viability.
(A)DNA content of HEK293 cells transiently transfected with a GFP empty
vector (EV) and GFP-tagged vectors for wild-type Aurora B and Aurora B
mutants (Aurora BK111M, Aurora BD205A and Aurora BK207R) and fixed 72 hours
after transfection. HEK293 GFP-positive cells were detected and used for cell-
cycle analysis. Overexpression of a SUMO-null Aurora-B protein (Aurora
BK207R) deregulates cell-cycle progression inducing polyploidy in the same
way as Aurora-BD205A kinase-dead form. (B)Bar graph quantification of
cellular DNA content, showing a dramatic increase of polyploidy in cells
overexpressing Aurora BD205A and Aurora BK207R mutants.
(C)Immunofluorescence (GFP, green; DAPI, blue) images revealing that cells
overexpressing Aurora BK207R are mostly multinucleated and display nuclear
aberrancies. Scale bars: 10m. (D)Colony-formation assay in U2OS cells
stably expressing GFP empty vector (EV) and GFP-tagged vectors for Aurora
B (wild-type and mutants). U2OS GFP-positive cells were sorted 48 hours
after transfection, replated in the presence of 1 mg/ml G418, then fixed 12
days later and stained with Crystal Violet to determine colony number. 50,000
GFP-positive cells were sorted and plated in 10 cm plates. (E)Quantification
of the number of macroscopic colonies per 10 cm plate showing a significant
(*P<0.001) reduction in the number of colonies in cells expressing Aurora
BD205A and Aurora BK207R.
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chromosomes and abnormal spindles (Fig. 6B). These defects
could be rescued by infection with retroviruses expressing wild-
type Aurora B, and Aurkb(/); Aurora BWT cells displayed normal
mitotic progression (about 60% mitotic cells were in metaphase,
anaphase or telophase) and resulted in normal cytokinesis. In these
Aurkb(/) MEFs, the exogenous Aurora B was properly located
at centromeres and migrated to the midzone during anaphase (Fig.
6B). By contrast, Aurkb(/); Aurora BK207R cells displayed
abnormal spindles and misaligned chromosomes and did not
progress to anaphase (about 10% of mitotic figures in metaphase,
anaphase or telophase). In these cells, the exogenous Aurora BK207R
displayed an abnormal centromeric concentration and remained
diffuse at chromosome arms (Fig. 6B).
Fluorescence recovery after photobleaching (FRAP) was then
used to compare the relative mobility of Aurora-B isoforms at
metaphase chromosomes and the mid-body. Wild-type Aurora B
showed a more dynamic behavior in the chromosomes located at
the metaphase plate than the other mutant isoforms (Fig. 7).
Although the recovery half-life (t1/2) was 35.6±10.2 seconds for
wild-type Aurora B (n7), the kinase-dead mutant Aurora BD205A
displayed a higher value (40.8±17.4 seconds; n4), as previously
reported in similar assays (Murata-Hori and Wang, 2002). A
significantly higher t1/2 value (119.9±36.8 seconds; n4) was scored
in the Aurora-BK207R mutant, suggesting defective dynamics in the
SUMO mutant protein. A similar recovery pattern for all the Aurora
B isoforms was observed at the mid-body [t1/244.00±30.5 seconds
in wild-type Aurora B (n4); t1/238.9±7.4 seconds in Aurora
BD205A (n3); t1/222.5±12.9 seconds in Aurora BK207R (n4)] (Fig.
7B,C) indicating a specific chromosomal defect in the dynamics of
Aurora B following mutation of the SUMOylation motif.
All together, these data indicate that Aurora BK207R is functionally
defective and suggest that SUMOylation at K207 is crucial to
regulate Aurora-B and INCENP dynamics at chromosomes.
The Aurora BK207R mutant displays no compromised
kinase activity
The differences in localization described above suggest that the
molecular defects caused by the kinase-dead and SUMO-null
mutations of Aurora B are not completely identical. We therefore
tested the effects of these two mutations on kinase activity.
Staining with phospho-specific antibodies against CENP-A, a
known Aurora-B substrate, reveals that phosphorylation of CENP-
A was significantly decreased in cells expressing either Aurora
BD205A or Aurora BK207R (Fig. 8A). By contrast, GFP-Aurora-
BWT, which was concentrated at centromeres, efficiently
phosphorylated CENP-A, resulting in positive staining for
phospho-CENP-A at kinetochores flanking the GFP-Aurora BWT
signal (Fig. 8A). We next directly tested the kinase activity of
V5-tagged Aurora-B proteins immunoprecipitated from transiently
transfected HEK293 cells (Fig. 8B). Aurora BK111M and Aurora
BD205A failed to efficiently phosphorylate the substrate MBP in
vitro, although Aurora BK111M still displayed some kinase activity,
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Fig. 4. Defective mitotic progression and cytokinesis in the presence
of Aurora BK207R. HeLa cells stably expressing siRNA-resistant mouse
Aurora B fused to GFP were nucleofected with human AURKB siRNA
oligonucleotides or a control siRNA and analyzed 36 hours after
nucleofection by immunoblotting and immunofluorescence.
(A)Generation and validation of HeLa stable cell lines by cytometry
cell-cycle analysis. The analysis of the total cell population is shown in
blue histograms, whereas the analysis of the GFP-positive population is
shown in orange histograms accompanied by the percentage of these
cells over the whole population. At least three different stable clones
were analyzed for each GFP-Aurora-B fusion protein. Depicted
histograms are from representative stable clones. (B)Western blot
analysis showing efficient depletion of human endogenous Aurora B
and protein levels of siRNA-resistant mouse GFP-Aurora-B proteins in
HeLa stable cell lines. Tubulin was used as loading control.
(C)Quantification of the percentage of interphase multinucleated cells.
Stable expression of GFP-Aurora-BD205A and Aurora-BK207R induces
accumulation of multinucleated cells (see picture) upon depletion of
endogenous Aurora B. Around 1000 interphase cells were counted per
point. (D)Quantification of the percentage of mitotic cells in
prometaphase (PM) or abnormal metaphases (AM) with misaligned
chromosomes (arrowheads) and multiple poles (arrows) revealing a
significant arrest at these stages in cells lacking the endogenous Aurora
B and stably expressing GFP-AuroraBD205A and -AuroraBK207R. About
50-100 mitotic cells were counted per point. Chemical inhibition of
Aurora-B kinase activity with ZM447439 (ZM1) was included in C and
D as a positive control. (E)Mitotic distribution of stable cell lines after
depletion of endogenous Aurora B. Expression of GFP-Aurora-BD205A
and -Aurora-BK207R provokes an arrest at prometaphase and a reduction
in cells at telophase. P, prophase; PM, prometaphase; M, metaphase; A,
anaphase; T, telophase. (F)GFP-Aurora-BD205A and -Aurora-BK207R
stable cell lines display a reduced number of cells undergoing
cytokinesis. In these mutant cells, the remaining cytokinesis figures are
usually abnormal with chromosomal bridges (arrow). -tubulin (-tub)
is in red, GFP-Aurora-B in green and DAPI (DNA) in blue. Scale bars:
10m.
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in agreement with the previous phenotypic analysis of these
kinase-dead mutants.
Strikingly, the kinase activity of the Aurora BK207R mutant was
not reduced at all and indeed it was slightly increased when
compared with the activity of the wild-type protein. Similar
results were obtained when a similar SUMO-defective mutant
(K141R) of the highly related kinase Aurora C was used (Fig.
8C). To further corroborate whether lack of SUMOylation
modulates the intrinsic kinase activity of these proteins, we
performed similar kinase assays in cells transfected with Aurora
B, SUMO2 and wild-type or dominant-negative forms of UBC9.
Interestingly, promoting Aurora-B SUMOylation by
overexpressing SUMO2 and UBC9 resulted in a slight overall
decrease in Aurora-B activity, whereas preventing SUMOylation
by expressing a dominant-negative form of UBC9 led to increased
Aurora B kinase activity (Fig. 8D). Finally, we also tested kinase
activity in human recombinant proteins produced in baculovirus.
As shown in Fig. 8E, the recombinant Aurora-BK202R mutant
(corresponding to mouse K207) was also active and displayed a
slight increase in kinase activity. Whether this increase represents
differences in the intrinsic kinase properties of the K202,K207
mutants, or is a consequence of impaired SUMOylation of the
wild-type molecule in mammalian or insect cells is not clear at
present. In any case, these results indicate that the functional
defects in the Aurora-BK207R mutant are not a consequence of
decreased kinase activity, but rather suggest that SUMOylation
modulates Aurora-B function by impairing its proper removal
from chromosome arms.
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Fig. 5. The Aurora-B K207 residue is required for proper localization of CPC proteins at the centromere. (A)Immunofluorescence images of HeLa stable
cell lines after depletion of endogenous Aurora B. Wild-type Aurora B colocalizes with INCENP at the centromeric regions. However, GFP-Aurora-BD205A and
-Aurora-BK207R mutants display a disperse localization over the chromatin that also affects to INCENP in PM/M cells. Multipolar spindles are also present in these
mutant cells (arrows). Scale bars: 10m. (B)Quantification of GFP-Aurora-B at chromosome arms from the centromere (Position 0; vertical arrow). Results are
means ± s.e.m. Scale bars: 5m. (C)Quantification of the percentage of PM/M cells in which GFP-Aurora-B fusions and INCENP are delocalized. Delocalization
of Aurora B is only observed in Aurora-BD205A and Aurora-BK207R mutants after depletion of the endogenous protein. At least 50 mitotic cells were counted per
point. (D)Images pseudo-coloured with Metamorph software to visualize the distribution of GFP-Aurora-B signal in stable cell lines after depletion of endogenous
Aurora B. Intensity of the signal is represented in a colour scale: (low) purple, blue, green, yellow, red (high). The contour of DNA (DAPI staining) is delineated.
Scale bars: 10m. (E)Quantification of the integrated optical density (OD) of GFP-Aurora-B signal over the chromatin shows a significant reduction (P<0.0001)
of GFP-Aurora-BK207R, but not -Aurora-BD205A, signal density. (F)Chemical inhibition of Aurora B with ZM1 does not delocalize the protein although it provokes
chromosome misalignment (arrows). -tubulin is in red in A, INCENP is in red in E, GFP-Aurora B is in green and DAPI (DNA) in blue. Scale bars: 10m.
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Discussion
Global mapping of the SUMO network by protein-protein
interactions and genetic-network analysis has linked SUMOylation
to many different biological processes, including chromosome
segregation and the cell cycle (Makhnevych et al., 2009). In recent
years, the SUMO pathway has been implicated in several aspects
of mitosis, including chromosome structure, cell-cycle progression,
kinetochore function and cytokinesis (Dasso, 2008; Watts, 2007).
In mammals, cells depleted of the SUMO E2-conjugating enzyme
UBC9 show major deficiencies in chromosome condensation and
segregation, along with severely altered nuclear morphology
(Hayashi et al., 2002; Nacerddine et al., 2005), revealing the
importance of this post-translational modification for mitotic
progression. The CPC has been widely proposed to be regulated
by SUMOylation. The yeast CPC component Bir1 (Survivin) is
known to be modified by SUMO (Montpetit et al., 2006) and Sli15
(INCENP) is also a candidate for SUMO modifications in this
organism (Wohlschlegel et al., 2004). Similarly, Borealin is
regulated by binding to SUMO2 and SUMO3 in human cells
(Klein et al., 2009).
In this work, we have identified a SUMO target site in
mammalian Aurora B and analyzed the consequences of lack of
SUMOylation in Aurora-B regulation and function. The
SUMOylation site is highly conserved among Aurora B orthologs
and in the other members of the Aurora family, Aurora A and
Aurora C. Our data indicate that Aurora B can be SUMOylated in
vivo by the three SUMO isoforms at Lys207 (K207). According to
observations in Xenopus egg extracts and human cells, SUMO2
and SUMO3 are found at centromeres and chromatin during
prometaphase and metaphase, whereas SUMO1 localizes to the
mitotic spindle and the spindle mid-zone during these stages
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Fig. 6. Aurora BK207R does not rescue mitotic defects in Aurora-B-
knockout MEFs. (A)Schematic representation of the protocol followed for
rescue upon acute deletion of Aurora B in quiescent cells. Primary (passage 2)
Aurkb(lox/lox) MEFs were seeded at 80% confluence and infected the
following day with retroviruses expressing Aurora-BWT or Aurora-BK207R.
Next day, cultures reach confluence and were cultured in 0.1% FBS and
infected with adenoviruses expressing Cre recombinase (AdCre). Two days
after the infection, cells were split in new plates at low confluence in the
presence of 10% FBS to induce entry into the cell cycle. Mitotic cells were
analyzed by immunofluorescence during the first round of division (28 hours
after splitting). (B)Acute deletion of Aurora B in MEFs provokes chromosome
misalignment and spindle defects that are rescued by exogenous, properly
localized, wild-type Aurora B [Aurkb(/); Aurora BWT; green signal in
merged images]. The exogenous Aurora BK207R, however, remains diffuse on
chromosome arms and it does not rescue the Aurkb-null defects resulting in
chromosome misalignment and impaired cytokinesis in Aurkb(/); Aurora
BK207R cells. DNA (DAPI; blue) is delineated in the insets. -tubulin is in red
in merged images. Scale bars: 10m.
Fig. 7. Defective dynamic localization of Aurora-B K207R at metaphase
chromosomes. HeLa cells stably expressing GFP-tagged Aurora-B isoforms
were used in a series of fluorescence recovery after photobleaching (FRAP)
experiments. (A)Representative cases of recovery of wild-type Aurora B,
Aurora BK207R and Aurora BD205A at the metaphase chromosomes.
Delocalization of the Aurora-B mutant isoforms is not obvious as in Fig. 4
because these cells express the endogenous Aurora-B protein.
(B)Representative images and quantification of similar FRAP assays at the
mid-body. Graphs in both cases show the curves obtained using a regression
analysis to integrate data from each stable clone. (C)The half-lives of GFP-
Aurora-B at metaphase chromosomes and mid-bodies were compared using a
t-test showing significant differences between the AurBK207R and the wild-type
forms. Results are means ± s.e.m.
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(Ayaydin and Dasso, 2004; Azuma and Dasso, 2002; Zhang et al.,
2008). Indeed, Aurora B and SUMO2 are known to colocalize
(Azuma et al., 2005) (our unpublished results), suggesting that this
kinase is preferentially modified by SUMO2, and possibly SUMO3,
in vivo.
Recent work has reported that Aurora B is not significantly
modified by SUMO1 in vitro and that it is not able to interact with
E2 SUMO-conjugating enzyme UBC9 or SUMO isoforms in yeast
two-hybrid assays (Klein et al., 2009). An intriguing possibility is
that other CPC components might be necessary for interactions
between Aurora B and the SUMOylation machinery. Indeed, Aurora
B seems to be modified by SUMO when immunoprecipitated from
cell extracts where the CPC integrity is maintained. In addition,
SUMOylation of Aurora B is favoured in vitro by the presence of
the IN-box domain of INCENP. Indeed, a computer simulation of
the interaction between these proteins suggests that the presence of
the IN-box domain of INCENP facilitates the proper energetic
environment required for SUMOylation of Aurora B (Fig. 9A,B).
How might SUMO modifications modulate Aurora-B function?
SUMOylation frequently alters protein surfaces and thereby
positively or negatively influences interactions with other
macromolecules (Geiss-Friedlander and Melchior, 2007). Thus,
SUMOylation can interfere with or promote protein-protein
interactions and provoke conformational changes in the modified
target. The consequences of those molecular changes might
influence the localization, stability or activity of a target protein in
vivo. As shown in this work, SUMOylation of Aurora B seems to
regulate the dynamics of Aurora-B localization at the chromosomes.
SUMOylation of Aurora B seems to affect a small fraction of the
Aurora B pool, although it is not clear at present whether this is a
consequence of the transient nature of SUMOylation or technical
problems owing to strong demodifying activity in mammalian
protein extracts (Geiss-Friedlander and Melchior, 2007; Pichler,
2008). Rescue experiments performed with the Aurora-B SUMO-
deficient form (Aurora BK207R) demonstrates that both Aurora B
and INCENP fail to concentrate in inner centromeres during
prometaphase or metaphase, thus suggesting that lack of Aurora-B
SUMOylation affects the localization of other CPC components.
Other examples of mitotic proteins whose localization at
kinetochores or centromeres is regulated by SUMO include the
kinesin CENP-E (Zhang et al., 2008), the CENP-H/I/K kinetochore
complex (Mukhopadhyay et al., 2010) and the GTPase-activating
protein RanGAP1 (Joseph et al., 2002).
It has been recently confirmed that phosphorylation of Aurora-
B substrates is influenced by the relative locations of the substrate
and kinase at the inner centromere (Liu et al., 2009). This
mechanism offers an efficient mechanism to selectively destabilize
improper microtubule-kinetochore attachments (Kelly and Funabiki,
2009). As described in the present manuscript, the SUMO-deficient
form of Aurora B, despite exhibiting normal kinase activity in
vitro, fails to phosphorylate CENP-A in vivo. Thus, the lack of
dynamic localization of SUMO-null Aurora B might impair its
interaction with its substrates, resulting in failure to phosphorylate
them in vivo but not in vitro.
SUMOylation of Aurora B might also directly modulate the
intrinsic kinase activity. Aurora-B D205 is crucial for kinase
function and it is only two residues upstream from the SUMO-
binding site (K207). Indeed, both residues are in the same structural
loop (Fig. 9B). Rescue experiments with a kinase-dead mutant
(Aurora BD205A) result in phenotypes that are similar to those
obtained with the SUMO-null (Aurora BK207R) mutant. This led us
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Fig. 8. Centromeric mislocalization of Aurora-BK207R mutant prevents
CENP-A phosphorylation without reducing its kinase activity.
(A)Immunofluorescence images from HeLa stable cell lines treated with siRNA
against endogenous Aurora B. GFP-Aurora-BD205A and -Aurora-BK207R mutants
accumulate along chromosome arms and fail to phosphorylate CENP-A. -
tubulin staining is in red (only merged in the mutant forms), phosphorylated
CENP-A, if present, is in red (only merged in the wild-type forms), GFP-
Aurora-B in green and DAPI (DNA) in blue. The inset represents proper
phosphorylation of CENP-A (red) by centromeric Aurora B (green). Scale bars:
10m. (B)In vitro kinase activity toward recombinant MBP of V5-tagged
Aurora B proteins. HEK293 cells were transiently transfected with the indicated
V5-Aurora-B expression vectors and the resulting exogenous expressed proteins
were immunoprecipitated with anti-V5 antibody. The kinase activity of a
SUMO-null (Aurora BK207R) Aurora B form is not reduced but partially
increased. Aurora-B kinase-dead mutants K111M and D205A were included as
negative controls of MBP phosphorylation. Quantification of [32P]MBP signal
was calculated considering the total amount of V5-Aurora-B protein in each
case. (C)Similar kinase assays using Aurora C constructs with the
corresponding kinase-dead (Aurora CK45M) or SUMO-null (Aurora CK141R)
mutations. (D)In vitro kinase assay in the presence of SUMO2, UBC9 or a
dominant-negative UBC9 form (C93S mutant). Whereas the overexpression of
SUMO2 and UBC9 results in decreased activity, the presence of UBC9 C93S
results in increased Aurora-B-kinase activity in this assay. Data were normalized
to the intensity of phosphorylated MBP in cells transfected only with wild-type
Aurora B. (E)Phosphorylation of histone H3 (P-H3) by recombinant human
wild-type (WT) Aurora B or the kinase-dead (K106R) and SUMO-null (K202R)
mutants. Data were normalized to total levels of human Aurora B (HsAurB).
Jo
ur
n
a
l o
f C
el
l S
cie
nc
e
to initially hypothesize that the Aurora-BK207R mutant is kinase
dead. However, this is not the case, as the kinase activity in vitro
is, if anything, slightly increased in this mutant and in a similar
mutant in Aurora C. Indeed, based on our kinase assays, the Aurora
BK207R mutant might act as a delocalized, partially hyperactive
mutant. A detailed examination of the predicted structure reveals
that SUMO binding might block the entrance of ATP to the kinase
and/or the transference of phosphate groups to a given substrate
(Fig. 9A,B). Therefore, it is reasonable to think that SUMOylation
might act as a transient and reversible means of inhibiting Aurora
B activity that is crucial for CPC localization and dynamics,
analogous to T14,Y15 phosphorylation of Cdk1, which also blocks
ATP binding and transfer. In general, our data are consistent with
a model where the non-SUMOylated, active CPC exerts its function
at unattached or merotelic kinetochores. Upon SUMOylation of
Aurora B, the kinase activity would be reduced and the
SUMOylated complexes can be removed from chromatin by an
unknown pathway that recognizes the SUMO residues (Fig. 9C).
In the Aurora-BK207R mutant, the Aurora-B kinase might be
hyperactive, as a result of the lack of SUMO residues, but the CPC
is diffuse over the chromatin, resulting in deficient localized
phosphorylation of its substrates.
Several lines of evidence link SUMO modifications with
ubiquitin-mediated processes (Geoffroy and Hay, 2009). Recent
studies have shown that ubiquitylation of Aurora B by the Cul3-
Klhl9/Klhl13 E3-ligase complex during early mitosis might serve
as a signal for its removal from chromosomes (Sumara et al.,
2007). The AAA-ATPase p97 complex specifically interacts with
ubiquitylated Aurora B and extracts it from chromosomes, leading
to inactivation of the kinase on chromatin (Ramadan et al., 2007).
In the absence of Cul3-Klhl9/Klhl13 activity, Aurora B is not
ubiquitylated and accumulates on chromosomes (Sumara et al.,
2007). The fission yeast Aurora kinase (Ark1p) interacts with two
RING-finger proteins that possess SUMO-interacting motifs
(SIMs), called Rfp1p and Rfp2p (Sun et al., 2007). These E3
ubiquitin ligases recognize SUMOylated proteins and
heterodimerize with Slx8, another RING-finger protein, to form a
functional ubiquitin ligase that is functionally similar to vertebrate
RNF4 (Geoffroy and Hay, 2009; Sun et al., 2007; Uzunova et al.,
2007). It is therefore possible that, in mammals, SUMOylation of
Aurora B facilitates the formation of a functional Cul3-
Klhl9/Klhl13 ligase complex during mitosis. Indeed, we have
found three predicted SIMs in each coadaptor, Klhl9 and Klhl13,
and one additional SIM in the Cul3 ligase that are conserved in
human and mouse in all cases (data not shown). It is also possible
that SUMOylation of Aurora B modulates its ubiquitylation by the
APC/C-Cdh1. However, Aurora B does not accumulate on
chromosomes upon RNA interference to knock down Cdh1 (Floyd
et al., 2008), suggesting that these two pathways are not linked.
Future experiments will be necessary to test and validate these
hypotheses.
In summary, our data suggest that Aurora-B function is
modulated by SUMOylation at K207. This modification is likely
to interfere with Aurora-B kinase activity and it might participate
in the extraction of the CPC from chromatin during prometaphase
and the metaphase-to-anaphase transition. The effects of
SUMOylation on the dynamic localization of Aurora B might be
linked to ubiquitylation by the Cul3-Klhl9/Klhl13 ligase, because
prevention of either SUMOylation or ubiquitylation by this complex
results in a similar phenotype where the CPC is delocalized on
chromosome arms. The regulation of Aurora B by SUMOylation
might also have relevant implications, not only in preventing
genomic instability, but also in tumorigenesis and cancer therapy
(Girdler et al., 2006; Keen and Taylor, 2004; Mo and Moschos,
2005; Perez de Castro et al., 2007; Perez de Castro et al., 2008).
Materials and Methods
Sequence analysis and gene constructs
For protein-domain analysis, we first used the ELM (Eukaryotic Linear Motif,
http://elm.eu.org) algorithm. To further confirm the presence of SUMO motifs we
used the specific SUMO prediction software SUMOplotTM Analysis Program
(http://www.abgent.com/tools/SUMOplot). Sequence alignments were obtained with
the Clustal software (http://www.ebi.ac.uk/Tools/clustalw2/index.html). Mouse Aurkb
cDNA was amplified by PCR from the plasmid mAA0155 (Mammalian Gene
Collection), cloned into pENTR-D-TOPO vector using TOPO technology (Invitrogen)
and transferred to a destiny vector coexpressing GFP or V5 tag by a LR recombination
reaction of the Gateway system (Invitrogen). Aurora-B mutants (Aurora BK111M,
Aurora BD205A and Aurora BK207R) were prepared using the Quik-Change site-
directed mutagenesis kit (Stratagene) and were verified by DNA sequencing. Plasmids
expressing histidine- or HA-tagged SUMO1, SUMO2 and SUMO3 as well as wild-
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Fig. 9. Modelling the Aurora-B-SUMO covalent interaction. (A)The
crystal structures of human SUMO2 (Reverter and Lima, 2006) (PDB 2I03)
and Xenopus Aurora B in complex with IN-box segment of INCENP (Sessa et
al., 2005) (PDB 2BFY) were used to simulate the interaction between these
molecules. SUMO2 might covalently bind the Aurora-B K207 residue (K218
in Xenopus crystal structure) through a finger composed of two glycine
residues. SUMOylation is not predicted to affect binding of the Aurora-B
partner and activator INCENP, but it might disturb the transfer of phosphate
groups to its substrates. (B)Details of the ATP-binding pocket showing the
localization of K111, D205 and K207 residues (K122, D216 and K218 in
Xenopus, respectively) used in this study. The position of the ATP molecule
was modelled after a superposition with the Aurora-A-TPX2 structure (PDB
1OL5). (C)A model for the role of SUMOylation of Aurora B in CPC
function. SUMOylation of Aurora B might result in decreased kinase activity,
probably as a consequence of interference of the SUMO residue with kinase
function. In addition, the presence of the SUMO residue might trigger an
unknown pathway that favours the removal of Aurora B and the CPC from
chromatin. MT, microtubule.
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type UBC9 or the UBC9 C93S mutant were kindly provided by Ron Hay (Wellcome
Trust Centre for Gene Regulation and Expression, University of Dundee, UK).
Cell culture, transfection and cell-cycle analysis
HEK293, U2OS and HeLa human cells were maintained in DMEM medium
supplemented with 10% fetal bovine serum and antibiotics and were grown at 37°C
in a humidified 5% CO2 atmosphere. The generation of conditional alleles at the
mouse Aurkb locus will be described elsewhere. Mouse embryo fibroblasts were
obtained from E14.5 Aurkb(lox/lox) embryos and cultured using routine protocols
(Garcia-Higuera et al., 2008). Human Aurora B was silenced using validated siRNA
oligos from Qiagen with the following sequence: 5-AACGCGGCACTTCA CA -
ATTGA-3. HEK293, U2OS and HeLa cells were transfected with 1 g plasmid
DNA using Effectene transfection reagent (Qiagen) according to the manufacturer’s
instructions. For silencing experiments, siRNA oligos were nucleofected in HeLa
cells using Amaxa kit and the conditions provided by Amaxa I13 program. Cell-
cycle distribution was determined by flow cytometry after DNA staining with
propidium iodide (Sigma) and analyzed on a FACSCanto flow cytometer (Becton
Dickinson). Data were processed using FACSDiva software (Becton Dickinson). For
chemical inhibition of Aurora B, HeLa cells were treated with 2 M ZM447439
(Tocris Bioscience). For acute deletion of Aurora B in MEFs, we followed the
scheme represented in Fig. 5A. Adenoviruses expressing Cre recombinase (Ad5
CMV-Cre) were obtained from The University of Iowa (Iowa City, IA). Adenoviral
infection was carried out during 2 days in a cell culture synchronized in G0 by serum
deprivation and confluence. Rescue experiments were performed with retroviral
vectors derived from pBabe-derivative plasmids expressing Aurora BWT and
AuroraK207R.
HeLa cells stably expressing His-SUMO2 (kindly provided by Ron Hay) were
transfected with His-SUMO2, UBC9 and V5-Aurora-WT and incubated for 24
hours. A parental asynchronous culture was used as a negative control. Taxol was
added at a concentration of 100 nM, and cells were incubated for an additional 18
hours. To obtain a G1 cell population, taxol-arrested cells were released in fresh
medium for 3 hours. Cell lysates and Ni-NTA pull-downs were performed as
described (Muller et al., 2000; Tatham et al., 2009).
Expression and analysis of recombinant proteins
Recombinant baculovirus-expressing human His-Aurora B-WT, His-Aurora B-
K106R and His-Aurora B-K202R were generated using the pFastBacHTA vector
and the Bac-to-Bac Expression System (Invitrogen), as described previously
(Gassmann et al., 2004). For in vitro SUMOylation assays, His-Aurora BWT or a
complex of His-Aurora BWT and the IN-box fragment (human INCENP amino acids
821 to end; Millipore) were incubated with purified E1-activating enzyme (SAE1/2),
E2-conjugating enzyme (UBC9) and either SUMO2 or mutant SUMO2 protein
(harbouring a proprietary mutation that impedes SUMO conjugation) in the presence
of ATP and following the manufacturer’s instructions (Active Motif).
Immunofluorescence and FRAP analysis
For immunofluorescence, cells were fixed with 4% PFA and permeabilized with
0.15% Triton X-100. These cells were then blocked with 3% BSA and incubated
with the primary antibodies against the following proteins: -tubulin (Sigma), Aurora
B (Abcam, BD Transduction), INCENP (Human GLPL serum, a gift from Manuel
Valdivia, Hospital Puerta del Mar, Cadiz, Spain), Phospho-CENP-A (Ser7; Upstate
Biotechnology). The matching secondary antibodies, with different Alexa Fluor dyes
(488, 594, 647), are from Molecular Probes (Invitrogen), Images were obtained
using a confocal ultraspectral microscope (Leica TCS-SP5) or an Olympus IX70
microscope controlled by Delta Vision SoftWorx (Applied Precision, Issequa, WA).
Image stacks were deconvolved, quick-projected and saved as tiff images to be
processed using Adobe Photoshop.
Fluorescence recovery after photobleaching (FRAP) was performed on HeLa
stable cell lines expressing GFP-Aurora-B wild-type and mutants (D205A and
K207R). All experiments were conducted using a FRAP-enabled DeltaVision. Images
of fluorescence recovery of centromeres and mid-bodies were captured every 20-30
seconds. Intensity values were normalized using the following equation; It(Xt–
Y)/(Z–Y), where I is the normalized intensity at time t, X is the actual intensity at
time t, Y is the intensity immediately following the photobleach (when t is equal to
zero), and Z is the intensity at the final time point. This sets the initial post-bleach
intensity (at t0 seconds) to zero and the final intensity to 1 arbitrary units. Regression
analysis was performed using the GraphPad Prism software by calculating the least
squares fit using the standard first order logarithmic equation. The t1/2 value was the
time at which the normalized intensity reaches 0.5 arbitrary units.
Protein extraction and analysis
For immunodetection in protein lysates, cells were washed twice with ice-cold PBS
and lysed in RIPA lysis buffer (37 mM NaCl, 0.5% NP-40, 0.1% SDS, 1% Triton
X-100, 20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 10% glycerol 1 mM PMSF)
supplemented with protease and phosphatase inhibitory cocktails (Sigma).
Additionally, for detecting SUMOylated proteins, an inhibitor of SUMO proteases,
N-ethylmaleimide (NEM), was added at 10 mM final concentration. After 30 minutes
on ice, samples were cleared by centrifugation. Proteins were separated on SDS-
PAGE, transferred to nitrocellulose membranes (Bio-Rad), probed using specific
antibodies and detected using goat anti-rabbit or anti-mouse secondary antibodies
(Dako) for ECL (Perkin Elmer) detection. After transfer of the protein lysates, we
probed nitrocellulose membranes with primary antibodies against Aurora B (BD
Transduction and Abcam), INCENP (Abcam), SUMO2/3 (MBL), Cyclin B1 (Santa
Cruz Biotechnology), p53 (Active Motif), HA tag (Abcam), V5 tag (Invitrogen),
His6 tag (Roche) and -tubulin (Sigma).
Immunoprecipitation and in vitro kinase assays
Total protein lysates extracted from HEK293 cells transiently transfected with V5-
tagged Aurora-B vectors were precleared with protein-G-agarose bead suspension
for 1 hour (Amersham). Supernatants were first incubated for 2 hours at 4°C on a
rotating wheel with mouse anti-V5 (Invitrogen) and later with 50 l of the blocked
bead suspension for an additional hour. Immunoprecipates were then washed three
times in RIPA buffer and, in case of the kinase assay, one extra wash was performed
with RIPA plus 0.5 M NaCl to remove possible bound unspecific kinases. One-fifth
of the immunoprecipitates bound to the beads were used for V5 detection by western
blot. For the kinase assay, four-fifths of the beads from the previous
immunoprecipitations or recombinant proteins (Millipore) were washed in kinase
assay buffer [10 mM HEPES-NaOH (pH 7.4), 150 mM NaCl, 10 mM MgCl2, and
1 mM EGTA] supplemented with 0.5 mM DTT and phosphatase inhibitor cocktail
(Calbiochem) and later incubated in 25 l of 2 kinase buffer supplemented with
0.2 mM ATP, 2.5 Ci [-32P]ATP and 3 g MBP (Sigma) or histone H3.1 (New
England Biolabs) as an Aurora substrate. The reactions were incubated for 30
minutes at 30°C, stopped by addition of 5 l of 5 Laemmli sample buffer, separated
by 12.5 % SDS-PAGE and analyzed by autoradiography.
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